Ulrich Broeckel, MD, is a physician-scientist with over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. His research efforts focus on the functional analysis of genome variation and the impact on therapeutic approaches. He is an expert in translational pharmacogenomics research and is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the NIH initiatives on clinical pharmacogenomics.
Pharmacogenetics of Cardiotoxicity: Disease Model and Clinical Testing Approaches
Cardiotoxicity emerged as a major complication for patients receiving certain chemotherapies. In this presentation we will review the current understanding on clinical testing. In addition, we will discuss approaches to elucidate underlying disease mechanisms to guide further understand the interindividual variability in response.
Philip Empey, UPitt
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.